Progestin-only contraception
Contraception for Adolescent and Young Adult Women, Page: 25-44
2014
- 2Citations
- 4Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
There are three main progestin-only contraceptives (POCs) available in the United States: progestin-only pills (containing norethindrone acetate), injectable depot medroxy progesterone acetate (DMPA or Depo-Provera® IM and SC forms) and the etonogestrel implant (Implanon® NEXPLANON®). POCs have advantages over combination methods for female adolescents with contraindications to estrogens because POCs carry very few cardiovascular risks and do not increase risk for thromboembolism. DMPA is particularly beneficial for female adolescents with sickle cell disease, seizure disorder, and for those taking anticonvulsants and other cytochrome p450 inducing medications. POCs also avoid adverse effects attributed to estrogens such as nausea, headache, edema and breast tenderness that often lead to poor adherence. Both DMPA and the etonogestrel implants are long-acting, convenient, discreet, and cost-effective methods that are highly desirable by female adolescents who may have difficulties adhering to coital, daily, weekly, or monthly, more user-dependent methods. POCs offer a safe, reversible, and effective alternative to combination contraceptive methods, with particular benefits and without the adverse effects or health risks associated with exogenous estrogens.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84929543976&origin=inward; http://dx.doi.org/10.1007/978-1-4614-6579-9_3; https://link.springer.com/10.1007/978-1-4614-6579-9_3; https://dx.doi.org/10.1007/978-1-4614-6579-9_3; https://link.springer.com/chapter/10.1007/978-1-4614-6579-9_3
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know